These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25552881)

  • 1. Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction.
    Sim DS; Jeong MH; Song HC; Kim J; Chong A; Bom HS; Jeong IS; Oh SG; Kim JM; Park DS; Kim JH; Lim KS; Kim MS; Ryu SH; Kim HK; Kim SS; Jang SY; Cho JY; Jeong HC; Lee KH; Park KH; Yoon NS; Yoon HJ; Kim KH; Hong YJ; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    J Korean Med Sci; 2015 Jan; 30(1):34-43. PubMed ID: 25552881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats.
    Chang SA; Lim BK; Lee YJ; Hong MK; Choi JO; Jeon ES
    J Korean Med Sci; 2015 May; 30(5):559-68. PubMed ID: 25931786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
    Kompa AR; Lu J; Weller TJ; Kelly DJ; Krum H; von Lueder TG; Wang BH
    Int J Cardiol; 2018 May; 258():192-198. PubMed ID: 29544929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia/reperfusion injury.
    Han J; Park SJ; Thu VT; Lee SR; Long le T; Kim HK; Kim N; Park SW; Jeon ES; Kim EJ; Yoon CH; Cho GY; Choi DJ
    Int J Cardiol; 2013 Oct; 168(3):2851-9. PubMed ID: 23642815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat.
    Jugdutt BI; Menon V
    J Cardiovasc Pharmacol Ther; 2003 Sep; 8(3):217-26. PubMed ID: 14506547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.
    Kang MG; Kim KI; Ihm SH; Rhee MY; Sohn IS; Lee HY; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
    Trials; 2019 Jul; 20(1):389. PubMed ID: 31262348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
    Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
    Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.
    Xu J; Carretero OA; Shesely EG; Rhaleb NE; Yang JJ; Bader M; Yang XP
    Exp Physiol; 2009 Mar; 94(3):322-9. PubMed ID: 19060116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
    Tao ZW; Huang YW; Xia Q; Xu QW
    Chin Med J (Engl); 2005 Jan; 118(2):146-54. PubMed ID: 15667801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
    Iimura O; Kusano E; Tanba K; Yanagiba S; Amemiya M; Ando Y; Honma S; Muto S; Asano Y
    Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiatherosclerotic effects of the novel angiotensin receptor antagonist Fimasartan on plaque progression and stability in a rabbit model: a double-blind placebo-controlled trial.
    Lee JY; Lee CW; Kim WJ; Ahn JM; Park DW; Kang SJ; Lee SW; Kim YH; Son WC; Jung S; Park SW; Park SJ
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):229-36. PubMed ID: 23615162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Effect of Fimasartan versus Valsartan on Blood Pressure Variability in Acute Ischemic Stroke: A Double-Blind Randomized Trial.
    Shin DH; Song S; Lee YB
    Cardiovasc Ther; 2019; 2019():7836527. PubMed ID: 31772615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.
    Lange SA; Wolf B; Schober K; Wunderlich C; Marquetant R; Weinbrenner C; Strasser RH
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):46-55. PubMed ID: 17261963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction.
    Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
    J Am Coll Cardiol; 2005 Mar; 45(5):661-7. PubMed ID: 15734608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.